Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ITHACA

Financiado

Digital Twin Technology to Predict Individual Response to Pharmacological Treatm...

Digital Twin Technology to Predict Individual Response to Pharmacological Treatments in Ovarian Cancer Personalised medicine (PM) is a novel approach to medical care that customises each treatment not just to the disease but also to the patient. While the advantages of this framework are widely recognised and its development is ack... ver más

31/08/2024

UNIBO

257K€

Presupuesto del proyecto: 257K€

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-08-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100%

4 Participantes

UNIBO

257.21K€ | Lider

AGROALIMENTARI MAS ULOT

261.55K€ | Participante

UNIVERSITY OF NEW SOUTH WALE...

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 51 meses Fecha Inicio: 2020-05-19
Fecha Fin: 2024-08-31

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA

TRL 4-5

Presupuesto del proyecto 257K€

Descripción del proyecto Personalised medicine (PM) is a novel approach to medical care that customises each treatment not just to the disease but also to the patient. While the advantages of this framework are widely recognised and its development is acknowledged as a fundamental societal challenge by the H2020 program, clinical applications are still limited, due to the increased complexity and costs, with respect to the current standard of care. ITHACA aims at developing an innovative PM toolkit that, relying on an advanced computational simulator, innovative in-vitro techniques and standard clinical data could provide an efficient and ethical framework for the screening of different ovarian cancer therapies and the identification of the most effective for each subject. This project builds on my experience with computational modelling and multidisciplinary research environments, to develop a programmable in-silico simulator capable of reproducing the patient-specific response to standard and novel ovarian cancer treatments. This tool will be extensively validated with both standard and primary cell lines and will then be used to determine patient-specific therapy outcome (RECIST 1.1 criteria) in women affected by ovarian cancer. Additionally it will be integrated in a novel bioreactor system for the in-vitro study of metastasization in HGSC. This compound device will allow for automatic treatment optimisation within an accurate and unique experimental model for this disease, and will thus provide an effective platform for personalised treatments development. Funding of this action will be a fundamental opportunity of career development, that will support my training in a highly innovative, interdisciplinary field while fostering the achievement of professional independence. Additionally the results of ITHACA will lead to high profile, impactful publications and provide the scientific community with enabling tools for the extensive application of PM in the clinic.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores